Antidote Founder and CEO to Present at DPharm Conference
Boston, MA (PRWEB) September 07, 2017 -- Antidote Technologies’ Founder and CEO, Pablo Graiver, will present “Clinical Trial Matching - Next Generation” at the 7th Annual DPharm: Disruptive Innovations to Advance Clinical Trials conference in Boston, which begins today. Antidote is the first clinical trial matching platform that connects patients to the right trials and helps researchers design trials to maximize participation.
The talk will be held at 12:15 pm ET on Friday, September 8, 2017. Joining Graiver in discussion will be Ed Godber, Antidote’s Entrepreneur-in-Residence and former Executive Vice President and General Manager of PatientsLikeMe Health. Together, Graiver and Godber will discuss the evolution of patient engagement for clinical trials and the growing necessity for a whole new approach.
“On the web, millions of people are starting to inquire about what's coming next in medical care and what trials are available,” said Graiver. “ We are providing the patient connections and matching technology so that finding a trial becomes as straightforward as finding a flight. On Friday at DPharm, I will demonstrate how Antidote is building this breakthrough ecosystem to help speed up the development of new treatments and cures.”
Also an Executive Sponsor of the DPharm Conference, the company will be exhibiting its Antidote Match platform at Booth 35. Match leverages Antidote-structured eligibility criteria, proprietary algorithms, and machine learning to explore a patient’s eligibility for every trial. It currently powers clinical trial search for 180+ leading patient organizations to reach millions of patients per month. This year, Antidote has made its clinical trial matching platform accessible to the pharmaceutical industry with Match API, a web and mobile app layer that allows any organization to match patients to their portfolio or program of trials and build insights along the way.
Antidote has also just announced an $11M funding round led by Merck Global Health Innovation Fund (GHI), Merck’s venture investment arm, conditional upon certain regulatory clearances being obtained, and is expected to be finalised later this year. Additional funders of this round include previous investors Smedvig Capital and Octopus Ventures.
“The investment by GHI is a testament to the approach taken by Antidote, which has profound implications for drug development,” said Godber. “In the future, all R&D SOPs should drive development teams to connect with millions of patients on a rapid loop to optimise how they set up their research, not waiting months to find out that a chosen form of execution will not deliver. Antidote’s matching technology and reach to millions of patients will help facilitate this new era of R&D.”
Antidote has structured eligibility criteria for more than 14,000 clinical trials and plans to reach full coverage next year with more capabilities, such as matching cancer patients to studies using mutation-level data.
“Since developing the first industry forum six years ago on how to think radically differently about how to perform clinical research, DPharm has grown to offer the widest range of new ideas,” says conference director Valerie Bowling. "We're thrilled to have Antidote join as an executive sponsor and look forward to their talk on the future of clinical trial matching."
For more information stop by booth 35 at DPharm or visit http://www.antidote.me/DPharm2017 to learn how Antidote can inform and accelerate clinical research.
About Antidote
Antidote is a digital health company on a mission to accelerate the breakthroughs of new treatments by bridging the gap between medical research and the people who need it. In a world where 80% of clinical trials are delayed or closed due to lack of participants, Antidote use cutting-edge technology to match the right patients with the right trials, helping medical researchers make faster progress, and offering new treatment options to patients. Antidote MatchTM, the company’s unique trial matching tool, currently powers clinical trial search for more than 180 patient communities and health portals — bringing clinical trial awareness, matching, and access to more than 15 million patients a month. Antidote was launched as TrialReach, and is based in the US and UK. As of today, the company has raised $26M. For more information, please visit http://www.antidote.me.
About the Conference Forum
The Conference Forum is a research firm that develops specialized events for professionals in the life science and healthcare industries. The company currently offers conferences for R&D leaders, clinical development professionals, biotech executives, VCs, drug delivery specialists, patient advocates and non-profit/government healthcare groups. The Conference Forum’s mission is to create the best content, facilitate the exchange ideas and provide quality networking to help move therapeutics to patients faster.
Media Contact
Sarah Kerruish
Chief Patient Officer, Antidote
sarah(at)antidote(dot)me
+44 07546364484
Sarah Kerruish, Antidote, http://www.antidote.me, +44 7546364484, [email protected]
Share this article